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In this project, an evidential reasoning model is built to amalgamate factors that could be used in 
early detection of pancreatic cancer. Our machine learning model outputs a probability of a given 
patient having prostate cancer based on various input variables. These variables include health 
history factors, such as smoking and medical history, technical artifacts, such as biopsy 
sequencing technology, and genomic biomarkers such as mutational, transcriptional and 
methylomic profiles, cfDNA, and copy number variation. The dataset used in this project is a 
part of The Cancer Genome Atlas (TCGA) project and was collected from the National Cancer 
Institute (NIH) Genomic Data Commons (GDC). The model is tested by varying input 
propositions and probability mass functions of input frames to create different combinations of 
input factors. Baseline prediction results in (0.084, 0.19) of not having pancreatic cancer. 
Prediction results were compared to the baseline prediction and a set of positive control 
expectations. For example, medium to high smoking history, medium to high drinking history 
with some cancer history will increase the posterior belief of a patient having pancreatic cancer 
to (0.091, 0.208). Presence of prognostic biomarkers will also increase the support for having 
pancreatic cancer, having medium impact DNA methylation and medium impact mRNA 
expression can lead the belief of having pancreatic cancer increase to (0.167, 0.273). 
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THE USE OF EVIDENTIAL REASONING MODEL WITH BIOMARKERS IN PANCREATIC CANCER PREDICTION 
 
I.   ​I​NTRODUCTION  
Pancreatic cancer is the result of uncontrolled division of malignant cells in the pancreas. 
With its late and few symptoms, pancreatic cancer is ranked as the fourth leading cause of 
cancer-related mortality worldwide [1]. The death toll recorded in 2015 from pancreatic cancer 
alone, among all the different types of cancer, was 411,600 deaths​ globally [2]. In the United 
States, it is the third-most-common cause of death [3]. It is more prevalent within the developed 
countries, accounting for about 70% of new cases recorded in 2012 [4]. 
It is quite a rare occurrence for patients below the ages of 40 to be diagnosed with this 
disease condition, while more than half of patients diagnosed with pancreatic adenocarcinoma 
are over 70 [5]. Ris​k factors associated with it are some rare genetic predisposition conditions, 
tobacco smoking, obesity and diabetes.  
Although expressed in various types, pancreatic cancer can be categorized into two 
groups, the exocrine and endocrine groups. 
● Exocrine group​: This group accounts for the vast majority of pancreatic cancer cases 
and occurs within the part of the pancreas responsible for digestive enzyme production, 
called the exocrine component. And among all types within this group, pancreatic ductal 
adenocarcinoma (PDAC) con​stitute over 90%, making it by far the most common type of 
pancreatic cancer cases [1​]​. This i​s quite the case despite the fact that the tissue it arises 
from constitutes only 10% of the pancreas cell volume, because it is just the duct within 
the pancreas ​[6]. ​The next most common type, representing about 5% of the exocrine 
group of cancers is called the acinar cell carcinoma[7]. Accounting for 1% of pancreatic 
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cancer cases is another type known as Cystadenocarcinomas [7]. Compared to other types 
of exocrine cancers, it has a better prognosis.  
● Endocrine group​: As for the second group, endocrine group of cancers, they account for 
the small minority types of cancer and are also called pancreatic neuroendocrine tumors 
(PanNet) [8]. These diverse groups of sometimes benign tumors arise from the body's 
neuroendocrine cells, which serves to integrate the endocrine and nervous systems. There 
are two types of endocrine group of cancers, the functioning and nonfunctioning types. 
The difference between both is the amount of hormones they secret. Functioning types, 
secret hormones in large quantities that often results in serious symptoms, favoring early 
detection. As for the second type, nonfunctioning PanNet, because they do not secrete 
hormones in sufficient quantities, it doesn't result in overt clinical symptoms and 
therefore are only diagnosed after it has spread to other body organs [8].  
The prognosis for pancreatic adenocarcinoma is very poor, as 25% survive one year after 
diagnosis and 5% live for five years; if detected early, it increases to 20% [4][9]. As for 
neuroendocrine types of cancer, they've got a better survival rate, of which after five years of 
diagnosis, 65% are living depending on the type of tumor [4]. Aside from the fact that the 
symptoms of PDAC ​do not ​usually appear at an early stage, they are not individually distinctive. 
Symptoms vary according to the cancer's location in the pancreas. While tumors in the body and 
tail of the pancreas express painful symptoms, those at the head typically cause dark urine, 
jaundice, loss of appetite and so on.  
2 
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To confirm diagnosis and its resectability, medical imaging techniques such as 
endoscopic ultrasound and computed tomography (CT scan) are employed. Abdominal 
ultrasound tends to miss small tumors but is effective in identifying cancers that have spread to 
the liver [10]. Pancreatic cancer is tackled using radiotherapy, chemotherapy, palliative care and 
undergoing surgery.  
II.   ​B​ACKGROUND  
Pancreatic cancer has such an alarming death rate because about 80-85% of patients are              
diagnosed when the disease has gotten to its late stage, and often already spread to other organs                 
[11]. At such a stage, curative surgical resection is not possible. However, it takes a period of                 
one or two decades between chronic pancreatitis diagnosis and an overt tumor [12]. Capitalizing              
on this long latency period will really curb the mortality rate when diagnosed early and treatment                
is commenced.  
A. Detection with Biomarker  
Compared to other tumors, such as those for lungs, breast, cervix and colon, the screening 
program for PDAC remains a challenge. Barrier hindering its progress includes the specificity of 
the test. This has led to lots of false cases because it requires a high performing screening test 
that's having a very high sensitivity. As a result of this, there has been an ongoing intensive effort 
aimed at discovering pancreatic cancer-associated biomarkers meant to assist in early detection, 
diagnosis and predicting response to treatment. These efforts have focused on serum biomarkers.  
A biomarker is any substance, molecule that is measured in the body and that can be used 
to predict the incidence or outcome of a disease. The absence of reliable biomarkers to capture 
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the early development of this disease, oftentimes, has resulted in patients being diagnosed when 
it's at an advanced or critical stage. So far, the US Food and Drug Administration (FDA) has 
approved only one biomarker associated with pancreatic cancer treatment, serum 
protein-carbohydrate antigen 19-9 (CA19-9 or sialylated Lewis antigen). 
Unfortunately, CA19-9 has not really been effective for early detection due to its low 
specificity and sensitivity. With a sensitivity of 79-81% and a specificity of 82-90%, it has a poor 
predictive value in asymptomatic patients [13].  Not only that other types of cancer can lead to 
elevated CA19-9 levels but about 10% of the Caucasian population lacks CA19-9 on their red 
blood cells [14]. Therefore, up to date, there's no reliable biomarker approved for early diagnosis 
of pancreatic cancer in clinical settings. 
Another vital role biomarkers play is that they can be used to monitor treatment efficacy 
and any resurgence of resected tumors. In fact, this is the function CA 19-9 currently serves, as 
they're used to provide valuable information regarding the patient's response to pancreatic cancer 
treatment. After the patient has been diagnosed of having pancreatic cancer, the healthcare team 
takes a baseline (initial) measurement of CA 19-9. As the patient commences treatment, the CA 
19-9 levels are continuously measured till completion of treatment. The changes recorded in 
these levels enable the doctors to ascertain if the tumor is growing, diminishing or staying the 
same size.  
Another biomarker that’s often under investigation is known as KRAS mutations, which 
occur in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) gene. Although these occur 
frequently in pancreatic cancer, its diagnostic accuracy is not sufficient enough for clinical 
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utilization. This is the result of  non-specificity of KRAS mutations as they are observed in many 
tumor types. From the extensive studies carried out, low levels of cell-free circulating DNA in 
serum were observed, thereby limiting  the use of non-invasive assays for clinical diagnostics 
[15]. Other biomarkers under investigation include various microRNAs, Macrophage inhibitory 
cytokine 1 (MIC1), Peptidylglycine Alpha-Amidating Monooxygenase (PAM 4), Glypican 
(GPCX), Osteopontin (SPP1), DNA methylation and RNA transcriptional profiles, copy number 
variation information, and signaling pathway-level aberrations. 
B. Sequencing 
Advances in DNA and RNA sequencing technologies provided scientists and clinicians           
with ability to understand the molecular differences between normal and malignant tissues​.            
Sequencing is the method of determining the sequence arrangement of DNA or RNA             
nucleotides. Different sequencing strategies have assisted with revealing new transformations          
tumor cells.  
Next-generation sequencing technology (NGS) has brought many important discoveries         
to cancer research and treatment. Finding the tumor driver genes and related signal transduction              
pathways has become a new strategy for current clinical tumor assessment and treatment. For              
example, study [16] includes a total of 22 patients with pancreatic cancer and 42 genes and 61                 
loci were detected by NGS to have DNA mutations. The mutation rate of TP53, KRAS,               
CDKN2A, SMAD4 genes is significantly higher than other genes. Researchers in [17] extract             
DNA from plasma samples and use NGS analysis methods to detect allelic mutation frequencies.              
The three most common KRAS mutations in blood samples of pancreatic cancer were screened              
by droplet digital PCR (dPCR). Through multivariate analysis, it is revealed that ctDNA in the               
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blood is a prognostic biomarker for patients with pancreatic cancer and is related to the               
development of the disease and the degree of tumor differentiation. As the tumor progresses, it               
sheds some of its DNA into the bloodstream. Blood-based assays can be utilized to detect DNA                
that came from malignant cells in pancreas. 
Advances in next-generation sequencing technologies also promote the development of          
whole-genome-sequencing (WGS) and whole-exome-sequencing (WES). While WES is capable         
of detecting mutations in the tumor exome, WGS can be used to detect all somatic mutations in                 
tumor samples.  
C. Machine Learning 
Massive cancer data has been generated as recent advances have taken place in the field of                
medicine. However, predicting an outcome correctly still remains challenging and fascinating for            
doctors and biomedical researchers. This has made Machine Learning (ML) methods an            
informative tool for medical sciences. ML techniques can model trends and associations from             
diverse data sets while accurately predicting diagnostic, therapeutic, and prognostic outcomes for            
each specific cancer type. 
Prognosis and prediction of diseases with various techniques and feature selection           
algorithms have widely applied in the last two decades [18]. Most of these initiatives use ML                
approaches to model cancer development and detect useful factors subsequently used in ML             
classifications. These methods use clinical, histological, and genomic data to model           
tumorigenesis. For almost three decades, leading ML techniques like Artificial Neural Networks            
(ANNs) and Decision Trees (DT) were used in cancer detection. Based on the investigation done               
by [19], more than 7,510 papers have been published to date on the topic of ML and cancer.                  
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Most publications use ML algorithms and incorporate heterogeneous tumor detection data and            
cancer prediction/forecast data. In the past decade, a trend has developed towards cancer             
detection and prediction, and other controlled teaching techniques have been noted. All these             
classification algorithms have been used across cancer types. 
D. Research on evidential reasoning 
When multimillion-dollar decisions are about to be made, hinging such decisions on                       
results obtained from traditional decision-analytic and probabilistic approaches is quite risky.                     
This is because, in practice, the true probability distribution of all factors might never be known                               
even if the requirements and assumptions the calculus requires are known. For better decision                           
making, the evidential-based approach was developed, with the works of Arthur Dempster and                         
Glenn Shafer serving as its basis [20]. The term "evidence" denotes that data are best treated                               
such that they either tend to support or refute to varying degrees probabilistic arguments of                             
different alternatives. Unlike traditional probabilistic techniques that require point estimations,                   
this technique makes use of interval estimations. A great advantage is that the prior data required                               
is more intuitive and easy to obtain. 
This project is an extension of former projects completed by Chandratre, and Sharghi             
[21][22]. The genomic dataset used in their studies are taken from the National Cancer Institute               
(NIH) Genomic Data Commons (GDC). Not only the outcome of the machine learning model              
with Support Vector Classifier (SVC) is used, their evidential reasoning (ER) model also takes              
other factors that may affect the predictions. For example, NGS technology used and sequencing              
reads could affect the outcome of machine learning prediction. The list of all inputs of their ER                 
model is: NGS technology, sequence read, smoking history, drinking history, family medical            
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history, patient medical history, biopsy site cell result, and amount of genetic material.             
Experiments done by adjusting the proposition and mass of input frames is consistent with              
intuitive judgement of the prediction [21][22]. 
Chandratre built on Sharghi’s project by creating an improved version of machine            
learning classifier by taking all projects in the NIH GDC portal into account. This includes               
22,872 genes and 3,142,246 total mutations related to these genes [22]. The improved model also               
considered the lethality of mutations, the impact of each mutation on the mutated protein can be                
classified as VEP, SIFT, and PolyPhen in NIH GDC portal. Sharghi’s model reported a high               
SVC prediction accuracy of ~91%, but only used gene-mutation combinations occurred in 185             
cases of the TCGA-PAAD dataset. Result of the improved model shows a low prediction              
accuracy ~85% with small standard deviation by considering VEP impact [22].  
E. Remaining technical gaps 
Current diagnostic approaches of detecting pancreatic cancer neglect to analyze the           
pancreatic disease in its early phase, bringing about a reduction in this current condition's              
survival rate. In addition, in the case of a fatal disease like pancreatic cancer, it has been proven                  
unreliable and imprecise to count on the limited resources available for analysis, including the              
Artificial Intelligence (AI)-assisted genomic data analysis and the few biomarkers known to be             
causative.  
The reasoning for this is that several variables contribute to the cell mutation in pancreas.               
These reasons might be personal habits (dietary habits, use of cigarettes, liquor intake, and so               
forth) or even inherited (hereditary conditions caused by certain germline genetic mutations). All             
these factors along with the available analytical data can be ambiguous, inconsistent, uncertain,             
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or even deficient. In correlation, if data regarding age and race of higher-risk people were to be                 
considered, maybe only a certain group of the larger population will be ultimately diagnosed              
[21]. 
To maximize the chance of correctly prognosis of pancreatic cancer, all different factors             
that could contribute to cancer development should be taken into consideration. Evidential            
reasoning model and the Belief Function (BF) thus become a crucial part to formulate rational               
and sound conclusions in relation to the probability of developing pancreatic cancer. This is              
accomplished more straightforwardly and less confining than standard analytical and          
probabilistic strategies [20].  
III.   A​PPROACH  
With a considerable development of research suggesting the presence of change of 
certain genetic material may lead to malignant tumors in their pancreas. This project tries to 
bring the gap in pancreatic cancer research to make predictions based not only on environmental 
factors, and factors that can affect machine learning outcome, but also try to incorporate 
biomarkers in addition to the work done by Chandratre and Sharghi.  
The biomarkers used in this project are namely: novel/rare mutation, pathway mutation, 
DNA methylation, cfDNA/cfDNA methylation, mRNA expression, exosome-miRNA, 
circulating tumor cell (CTC), and copy number variation (CNV). (Check Appendix C to J for 
more information regarding each biomarker).  
Each biomarker is used as an input frame in the project, frames are mutually exclusive 
random variables. The collection of frames is called a galley. This project contains a galley file 
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that records information for each frame: frame name, frame type, propositions, input node, 
output node, and compatrel relationship between frames. Proposition is a value of the frame, the 
set of propositions in a frame is mutually exclusive and exhaustive in the BF world. Frame type 
indicates if the propositions are discrete or continuous. For example, the outcome of a machine 
learning prediction can be PC or NOT_PC, they are discrete propositions of ML_PREDICTION 
frame. For each frame, a ​probability value representing a degree of belief denoted as “mass” is 
assigned to the subset of propositions of the frame. The baseline proposition and mass can be 
found in Appendix A Table I. For example, the baseline mass 0.5 is assigned to LOW_IMPACT 
proposition of the DNA methylation frame, it represents there’s 0.5 confidence from the 
evidence that supports DNA methylation frame has low impact. The remaining mass of 0.5 
means DNA methylation could be either LOW_IMPACT, MEDIUM_IMPACT, or 
HIGH_IMPACT. In another case, cfDNA/cfDNA methylation frame has a vacuous mass of 1.0 
assigned to the proposition set (LOW_IMPACT, MEDIUM_IMPACT, HIGH_IMPACT), which 
means that mass 1.0 is assigned to a disjunction of of the set of all propositions in the frame. 
Although there are many studies on biomarker, the current researches show different 
degrees of understanding of the role of each biomarker in pancreatic cancer prediction. A 
discount value is assigned to each frame to decrease the impact of conviction for the 
predisposition of this frame to pancreatic cancer. For example, CNV is assigned a higher 
discount rate, because research papers like [23] mention that the correlation between CNV and 
pancreatic cancer need to be elucidated by further investigation. Compared to NGS technology 
which provides concrete data, smoking history or drinking history has a higher discount rate, 
because they could be inaccurate and subjective. The value of discount rate is selected based on 
10 
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subjective estimation. When a discount rate of 0.7 is applied, only 70% of the mass will be used 
in the calculation.  
 The evidential model sets up the conviction of predicting pancreatic malignancy relying 
upon the combination of propositions and their masses as inputs. Frames are combined based on 
Dempster’s rule of combination. Some frames map directly to calculating the chance of having 
pancreatic cancer, while a disjunction of related frames can also form intermediate nodes. These 
intermediate nodes aggregate the evidence provided by the input nodes. For example, an 
intermediate node is created using BIOPSY_SITE_CELL_RESULT and 
AMOUNT_GEN_MATERIAL as direct input nodes, since the different amount of material 
taken at a biopsy site may affect sequencing and ML outcome. There’s also an intermediate node 
created between SMOKING_HISTORY, DRINKING_HISTORY, FAMILY_MED_HISTORY, 
and PATIENT_MED_HISTORY, because as [24] has shown, there is a high co-occurrence 
between smoking and drinking behaviors, and smoking and drinking habits will tend to result in 
medical conditions.  Figure 1 and Figure 2 shows all the input frames and intermediate nodes for 
this project.  
11 
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IV.   E​XPERIMENTS 
Our evidential reasoning model is tested by adjusting the proposition and mass of the 
input frames to see if the prediction is expected. The ER prediction using all frames with 
baseline inputs mass, proposition, and discount rate gives the following output: 
Belief Of Having Pancreatic Cancer Lies Between:      (0.084, 0.19) (0)|**--------|(1) 
Belief Of Not Having Pancreatic Cancer Lies Between:  (0.809, 0.915) (0)|--------**|(1) 
 
The following experiments aim to demonstrate how adjusting input factors affect the final 
prediction. A updating program is used to update the mass and propositions for input frames, 
information about how the program is used can be found in Appendix K.  
 
A. ER Experiment 1 
Since there’s an intermediate node created for BIOPSY_SITE_CELL_RESULT and 
AMOUNT_GEN_MATERIAL. This experiment aims to demonstrate how change in biopsy 
sites, and the amount of genetic material taken from the biopsy site affects the result of the 
prediction. Adjust the two frames and keep the values of all other input parameters the same as 
the baseline values. The prediction results are shown in the following table: 
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Biopsy site  Amount of genetic 
material 
Belief Of Having 
Pancreatic Cancer 
Lies Between: 
Belief Of Not 
Having Pancreatic 
Cancer Lies 
Between: Proposition Mass Proposition Mass 
NEAR_PAN_
IRREG 
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Table 1. Prediction result of various input parameters for biopsy site and amount of material 
  
From the table above we can see that when the biopsy site is NEAR_PAN_IRREG, 
NEAR_PAN_REG, or NOT_NEAR_PAN_REG, change the amount of genetic material from 
SMALL to MEDIUM or HIGH, will lead to an increase in the belief of having pancreatic cancer.  
When the biopsy site is NOT_NEAR_PAN_IRREG with mass 0.7, change the amount of 
material from SMALL to LARGE, the prediction doesn’t change. When the biopsy site is 
NEAR_PAN_IRREG with MEDIUM amount of genetic material, increasing the mass from 0.3 
to 0.7 also leads to an increase in the belief of having pancreatic cancer. 
 
B. ER Experiment 2 
An intermediate node is created between SMOKING_HISTORY, 
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experiment tests how varying mass distribution and proposition affects the result of prediction. 
Adjust the four frames and keep the values of all other input parameters the same as the baseline 
values. The prediction results are shown in the following table: 
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Smoking history Drinking history Family med. history Patient med. history 
Proposition Mass Proposition Mass Proposition Mass Proposition Mass 





Belief Of Having Pancreatic Cancer Lies Between:     (0.092, 0.207)(0)|***-------|(1) 
Belief Of Not Having Pancreatic Cancer Lies Between: (0.792, 0.907)(0)|-------***|(1) 





Belief Of Having Pancreatic Cancer Lies Between:     (0.085, 0.191)(0)|**--------|(1) 
Belief Of Not Having Pancreatic Cancer Lies Between: (0.808, 0.914)(0)|--------**|(1) 





Belief Of Having Pancreatic Cancer Lies Between:     (0.092, 0.207)(0)|***-------|(1) 
Belief Of Not Having Pancreatic Cancer Lies Between: (0.792, 0.907)(0)|-------***|(1) 





Belief Of Having Pancreatic Cancer Lies Between:     (0.091, 0.208)(0)|***-------|(1) 
Belief Of Not Having Pancreatic Cancer Lies Between: (0.791, 0.908)(0)|-------***|(1) 





Belief Of Having Pancreatic Cancer Lies Between:     (0.092, 0.208)(0)|***-------|(1) 
Belief Of Not Having Pancreatic Cancer Lies Between: (0.791, 0.907)(0)|-------***|(1) 
HIGH 0.3 HIGH 0.3 CANCER 0.3 CANCER 0.3 
Belief Of Having Pancreatic Cancer Lies Between:     (0.092, 0.207)(0)|***-------|(1) 
Belief Of Not Having Pancreatic Cancer Lies Between: (0.792, 0.907)(0)|-------***|(1) 
HIGH 0.7 HIGH 0.7 CANCER 0.7 CANCER 0.7 
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Table 2. Prediction result of various input parameters for smoking history, drinking history, 
family medical history, and patient medical history 
 
From the above table, we can see that when propositions are LOW or NO_CANCER, 
increasing the mass of the four propositions from 0.3 to 0.7,  will lead to an increase in the belief 
of not having pancreatic cancer. When the propositions are of high correlation will cause 
pancreatic cancer, increasing the mass from 0.3 to 0.7 increases the prediction of probability of 
having pancreatic cancer. When the propositions are of MEDIUM or SOME_CANCER, change 
in mass doesn’t lead to a change in the prediction. In addition, we can observe that when keeping 
mass the same for all four propositions, changing propositions from MEDIUM to HIGH lead to 
an increase in the chance of having pancreatic cancer. The results match with expectation. 
 
C. ER Experiment 3 
Since there’s an intermediate node created for NOVEL_MUTATION and 
PATHWAY_MUTATION. This experiment aims to demonstrate how novel mutation, pathway 
mutation affects the result of prediction. Adjust the two frames and keep the values of all other 
input parameters the same as the baseline values. The prediction results are shown in the 
following table: 
17 
Belief Of Having Pancreatic Cancer Lies Between:     (0.109, 0.223)(0)|-**-------|(1) 
Belief Of Not Having Pancreatic Cancer Lies Between: (0.776, 0.89)(0)|-------**-|(1) 
Novel mutation  Pathway mutation Belief Of Having 
Pancreatic Cancer 
Lies Between: 




Proposition Mass Proposition Mass 
NOT_NOVEL 0.7 LOW_ 
IMPACT 
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Table 3. Prediction result of various input parameters for novel mutation and pathway mutation 
 
Compared to the baseline prediction when propositions are NOT_NOVEL and 
LOW_IMPACT with both masses being 0.5, increasing mass to 0,7 caused a slight increase in 
the belief of not having pancreatic cancer. But in general not much variation is observed across 
all predictions, this is because there’s not much variation in the compatrel relationships of the 
intermediate frame BIO_LOC_X_AMT. MEDIUM_IMPACT or HIGH_IMPACT pathway 
mutation could both lead to pancreatic cancer. Mutation being NOVEL or NOT_NOVEL could 
both lead to pancreatic cancer.  
 
D. ER Experiment 4 
Since there’s an intermediate node created for DNA_METHYLATION, 
cfDNA_METHYLATION and mRNA_EXPRESSION. The proposition of cfDNA methylation 
is always (LOW_IMPACT, MEDIUM_IMPACT, HIGH_IMPACT) is always 1.0 (Check 
Appendix F for more details). This experiment aims to demonstrate how changes in DNA 
18 
NOVEL 0.7 LOW_ 
IMPACT 




NOT_NOVEL 0.3 MEDIUM_ 
IMPACT 




NOT_NOVEL 0.7 MEDIUM_ 
IMPACT 




NOVEL 0.7 MEDIUM_ 
IMPACT 




NOT_NOVEL 0.7 HIGH_ 
IMPACT 




NOVEL 0.7 HIGH_ 
IMPACT 
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methylation, mRNA expression affects the result of prediction. Adjust the three frames and keep 
the values of all other input parameters the same as the baseline values. The prediction results are 
shown in the following table: 
 
Table 4. Prediction result of various input parameters for DNA methylation, cfDNA methylation, 
and RNA expression. 
 
When the propositions are of LOW_IMPACT, an increase in the mass from 0.3 to 0.7 
doesn’t lead to much change in the belief of not having pancreatic cancer. When the proposition 
is of MEDIUM_IMPACT or HIGH_IMPACT, an increase in the mass from 0.3 to 0.7 will cause 
an increase in the belief of having pancreatic cancer. The belief of having pancreatic cancer is 
higher when the proposition is HIGH_IMPACT or MEDIUM_IMPACT, compared to when the 
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proposition is LOW_IMPACT. The prediction doesn’t change much when changes made from 
MEDIUM_IMPACT to HIGH_IMPACT. 
  
E. ER Experiment 5 
Circulating Tumor Cells (CTC) is a new biomarker frame added to the ER model with no 
intermediate nodes between other frames. This experiment demonstrates how adjusting this 
frame affects the final result when keeping other values the same. Set CTC to the following 
parameters and run the program: 
 
Table 5. Prediction result of various input parameters for CTC.  
 
When the proposition is of LOW, an increase in the mass from 0.3 to 0.7 will cause an 
increase in the belief of not having pancreatic cancer. When the proposition is of MEDIUM or 
HIGH, an increase in the mass from 0.3 to 0.7 will cause an increase in the belief of having 
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pancreatic cancer. The belief of having pancreatic cancer is higher when the proposition is HIGH 
or MEDIUM, compared to when the proposition is LOW. The prediction doesn’t change much 
when changes made from MEDIUM to HIGH. 
 
F. ER Experiment 6 
CNV is a new biomarker frame added to the ER model with no intermediate nodes 
between other frames. This experiment demonstrates how adjusting this frame affects the final 
result when keeping other values the same. Set CNV to the following parameters and run the 
program: 
 
Table 6. Prediction result of various input parameters for CNV.  
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When the proposition is of LOW_IMPACT, an increase in the mass from 0.3 to 0.7 will 
cause an increase in the belief of not having pancreatic cancer. When the proposition is of 
MEDIUM_IMPACT, the prediction remains the same as the mass changes. When the 
proposition is of HIGH_IMPACT, an increase in the mass from 0.3 to 0.7 will cause an increase 
in the belief of having pancreatic cancer. The belief of having pancreatic cancer increases when 
the impact of proposition increases when keeping the mass the same.  
V.   C​ONCLUSION​ ​AND​ A​NALYSIS 
Overall, the outcome of ER prediction matches with expectation, that increase in the 
mass of a proposition, doesn’t change the direction of prediction, but will increase the belief in 
the prediction. Sometimes changes in the proposition do not cause change in the prediction. This 
is because the different combination of the compateral relationship could lead to the same 
prediction in the galley definition. The hyperparameters can be fine tuned by assigning a frame 
continuous proposition type and may create more variation in the compateral relationships. It is 
observed that variation in frames that do not connect to intermediate nodes create a greater 
impact in the magnitude in the prediction, compared to those connected to intermediate frames. 
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VI.   F​UTURE​ W​ORK  
Some other prognostic factors that lead to pancreatic cancer could also be added to the 
current model. Studies of proteomics, metabolomics have revealed certain proteins and miRNA 
can be potential biomarkers for detecting pancreatic cancer. Other factors including dietary 
habits, allergies, and some ecological factors may also lead to a higher chance of getting 
pancreatic cancer, which hasn’t been considered in our project. Secondly, the genomic data of 
this project is gathered from The Cancer Genome Atlas Program (TCGA), which only has 185 
cases in the pancreatic adenocarcinoma project. This creates an imbalance in the dataset, as 
pancreatic cancer cases are only a small portion in the whole dataset [22]. Therefore, more data 
for pancreatic cancer data is desired. Due to COVID-19 social distancing restrictions, our project 
is not able to sequence real pancreatic cancer tissue from the California State University (CSU) 
East Bay lab. In the future, the credibility of this ER model could be further validated if genomic 
data from real tumor samples could be used. Moreover, since the discount value decreases the 
credibility of each input frame in prediction, more research needs to be done to justify if the 
discount values are appropriate. In addition, there are so many different combinations of 
propositions and masses of different frames. From the experiments we can observe that some 
frames have greater impacts on the magnitude of prediction than others. More parameter tuning 
needs to be done to find the desired mass for each frame, or even for each proposition. More in 
depth research may help to find the data to back up the mass value assigned to each frame.The 
next phase of this project should also collect genomic data for testing each biomarker to verify if 
the prediction is correct. 
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A​PPENDIX​ A 
 




Frames Assigned Proposition Support 
ML_PREDICTION NOT_PC 0.5 
NGS_TECH ionTorrent 0.5 
SEQ_READ LOW_GC_x_LOW_HMR 0.5 
SMOKING_HISTORY LOW 0.5 
DRINKING_HISTORY LOW 0.5 
FAMILY_MED_HISTORY NO_CANCER 0.5 
PATIENT_MED_HISTORY NO_CANCER 0.5 
BIOPSY_SITE_CELL_RESULT NOT_NEAR_PAN_IRREG 0.5 
AMOUNT_GEN_MATERIAL SMALL 0.5 
NOVEL_MUTATION NOT_NOVEL 0.5 
PATHWAY_MUTATION LOW_IMPACT 0.5 





mRNA_EXPRESSION LOW_IMPACT 0.5 
EXOSOME_MiRNA LOW_IMPACT 0.5 
CNV LOW_IMPACT 0.5 
CTC LOW 0.5 
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A​PPENDIX​ B 
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A​PPENDIX​ C 
Novel Mutation 
There are more and more discoveries of novel mutations that would increase the chance 
of developing pancreatic cancer. [25] describes one of the largest whole-genome association 
studies, where more than 11.3 million variants were analyzed in more than 21,536 persons. 
Among these genetic donors, 9,040 are pancreatic cancer patients and 12,946 are healthy 
individuals of European descent. It involved researchers from the National Cancer Institute, 
Johns Hopkins Kimmel Cancer Center and other collaborators from over 80 other worldwide 
institutions.  
From the study, five novel genetic changes were identified to have linkage to increasing 
pancreatic cancer risk. Commenting on this study, Alison Klein, a professor of oncology, 
pathology and epidemiology, highlighted that a holistic consideration of all five variants is vital 
in understanding pancreatic cancer development. On an individual basis, though these variants 
can result in modest changes, they aren't sufficient as indicators of pancreatic cancer detection. 
These variants are located on the human chromosomes 1, 7, 8, 17. One of the variants 
was found in a protein-coding gene, NOC2L, which binds directly to gene p53, which drives 
pancreatic cancer development. This then binds with another variant, a tumor gene, p63,  that's 
associated with increased pancreatic cancer risk.  
The third variant was identified in the HNF4G and HNF1B genes, they are growth factors 
that regulate cell growth. The next variant was found near the GRP gene, which is associated 
with the regulation of gastrointestinal hormones. And the final variant was found on the TNS3 
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gene, which possibly aids metastasis. According to the study leader, Alison Klein, PH.D., 
M.H.S., changes of these five identified regions increases the risk of getting pancreatic cancer 
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Appendix D 
Pathway mutation 
Pancreatic cancer genomes are characterized by several genetic mutations which aid the 
development and progression of neoplastic lesions. Driver mutations such as K-Ras, initiate the 
disease development while passenger mutations like phosphoinositide-3-kinase (PI3K), 
CDKN2A and ERBB2, amplify its progression.  
PDAC are genetically heterogeneous tumors of which K-Ras are the first detected major             
driver mutations during progression in over 90% of patients, constituting the most frequently             
mutated oncoprotein [26]. Mutated K-Ras activates several downstream effector-signalling         
pathways like PI3K, which are linked with migration, proliferation and metastasis. In PDAC             
patients, the most common K-Ras mutation points are G12D and G12V. 
As for PI3K signalling pathway, studies have indicated that they inhibit cellular apoptosis             
and stimulate the proliferation of cancerous cells. An estimate of about 60% of PDAC patients               
have a deregulated PI3K/Akt signalling pathway [27]. There are three classes of PI3Ks, grouped              
as Class I, Class II and Class III. And studies have indicated that the Class I PI3K are more                   
responsible for the proliferation of pancreatic cancers. It modulates downstream signalling           
cascades in response to stimuli from several growth factor receptors on the cancerous cell surface               
[27].  
Also, serine-threonine kinase (Akt) functions as regulators of diverse cellular processes           
that are very vital for cell growth. Development of a screening methodology that's highly              
sensitive in analyzing the high incidences of mutations in the PI3K signalling pathway will aid               
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the early detection of pancreatic cancers. Also, asides from early detection, understanding            
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Appendix E 
DNA methylation 
DNA methylation is a biological process that occurs when methyl group bonds with the 
carbon 5 of cytosines from a DNA molecule, to form 5-methylcytosine (5mC), due to a DNA 
methyltransferases mediated covalent addition [28].  
DNA methylation is vital in the progression of cancers. When found at the regulatory 
regions of a gene, it results in the transcription of such a gene being suppressed. It alters the 
chromatin structure and silences the tumor suppressor gene or activates oncogenes.  
The use of DNA methylation analysis promises to be effective because cfDNA are more 
informative, sensitive and carries methylation markers that makes it easier to identify 
tissue-specific cell death. It is interesting to note that DNA methylation profiles appear very 
similar when originating from the same tissue. So scientists are able to decipher the 
heterogeneous signals emanating from a cfDNA pool to locate the originating tissues [29]. 
Some notable methods used in the assessment of DNA methylation include 
Methylation-specific PCR (MSP), Quantitative Methylation Specific PCR (QMSP), Targeted 
Amplicon Sequencing, and a whole lot of others [30]. A large number of these methods are 
dependent on the relatively fast deamination of unmethylated cytosines into uracils [28].  A 
recent study [30] of the methylation profile of genes ADAMTS1 and BNC1, found the promoter 
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Appendix F 
Cell-free DNA/cfDNA methylation 
In carrying out screening for pancreatic cancers, the analysis of pancreatic juice can 
provide more information when compared to other forms of analysis. But it is a more 
cumbersome and invasive means of obtaining specimen samples. This has led to the exploration 
of other sensitive and non-invasive methods for early detection.  
Right now one worthy approach involves the study of circulating cell-free DNA 
(cfDNA), which are carriers of specific markers that help to identify certain cell death. cfDNA 
refers to degraded DNA fragments that are released into the blood plasma. It is made up of short 
double-stranded segments of nucleic acids. Analysis of cfDNA presents a minimally 
non-invasive approach as they are present as polynucleotide chains of 0.1-20 kilobase-base pairs 
in the plasma and serum [29].  
Increased levels of cfDNA in the plasma can be as a result of stroke, trauma or even 
strenuous exercises, but its concentration can't be compared to those of a cancer patient. While a 
healthy individual's cfDNA concentration can range from 0 to 100 ng/ml of blood, a cancerous 
patient presents an average of 4 to 40 times increased levels [29]. So invariably, the higher the 
plasmatic cfDNA levels observed, the higher the cancer's cellular turnover. cfDNA are carriers 
of markers for KRAS and DNA methylation signatures. Once cfDNA is sequenced, the genetic 
information of a tumor becomes available since all tumors exhibit genetic alterations. 
A major hurdle encountered with the circulating cfDNA is that certain factors limit the 
information provided by the genetic sequence. Together, factors such as heterogeneous genetic 
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background, inter-individual variability of plasmatic levels and having diverse origin from both 
healthy and neoplastic cells, makes the interpretation of its sequence data cumbersome. 
Nevertheless, analyzing the sequence data obtained from the circulating cfDNA is a method that 
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Appendix G 
mRNA-expression 
In addition to DNAs, protein-coding mRNAs from the tumor tissues are released into the 
blood, and can reflect changes in tumor specific gene expression. Combined with advances in 
molecular diagnostics, systematic profiling of cell free m-RNA can improve our understanding 
of cancer pathology and identify novel biomarkers for early detection, without the need for 
invasive biopsy. 
Certain cell-free m-RNA species are in complexed forms that protect them from            
degradation by RNases [31]. This ensures their stability in the circulation, in contrast to              
complex-free RNA, which is rapidly degraded. Therefore, key challenges in the cell free m-RNA              
testing include its extremely low abundance, susceptible to degradation, relatively unstable and            
poor extraction efficiency. Circulating cell free m-RNA carries information from human tissues;            
the pattern of cell free m-RNA expression reflects cancer cell growth and reproduction,             
dysfunction of cancer immunity, which makes cell free m-RNA expression signature a promising             
biomarker for early diagnostic, prognostic and therapeutic purposes [32]. 
While several research reports have shown impressive promises of circulating cell free            
m-RNA, there’s still a lot more need to be learned in this field. The advantage of using                 
circulating cell free m-RNA is that, compared to protein biomarkers, PCR can be used in               
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Appendix H 
Exosomes-miRNA 
Exosomes are membrane-bound extracellular vesicles that are generated by the          
endosomal compartment, functioning as prominent mediators of intercellular communication         
[34]. So, through the transfer of biological materials, they instruct, regulate and re-educate their              
microenvironment and target organs. Some of the components of exosomes include lipids,            
proteins and nucleic acids such as DNA, microRNA (miRNA) and so on. Analysis of exosomes               
offers a minimally invasive or non-invasive method because they are easily isolated and             
identified in body fluids. 
For early detection, exosome-microRNA holds a lot of potential as an effective            
biomarker. miRNA is a small non-coding RNA molecule of about 19-25 nucleotides, invariably             
regulating gene expression in almost all cellular processes, including carcinogenesis [34]. Their            
dysfunction often results in the initiation, growth and spread of cancer.  
The signature profile of a pancreatic cancer's miRNA is very different when compared             
with that of a normal pancreatic cell. And they tend to be upregulated in patients diagnosed of                 
having pancreatic cancers than those with benign pancreatic disorders. So when achieved, an             
exosomal miRNA-based detection can aid in early detection of dysfunctional miRNA at its             
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Appendix I 
CTC 
Circulating tumor cells(CTC) refers to detached cells emanating from a primary tumor that's in 
circulation in the bloodstream. CTCs are capable of metastasizing in distant organs as offshoots 
of their primary tumor. Invariably, this means that CTCs tend to be upregulated as the disease 
progresses, serving as an indicator for cancer progression.  
Although, due to metastatic inefficiency, only an estimated 0.01% of CTCs progresses to 
form metastases, accounting for its rarity in per millimetre of blood [35]. Still yet, 
notwithstanding the fact that it can't exclusively indicate clinically significant macro-metastases, 
it certainly indicates the presence of malignant tumors which can aid in the early prognosis of 
pancreatic cancer.  
As a result of their low frequency in per milliliter of blood, detection and isolation are 
quite difficult. Thus, it employs a two-step procedure for isolation: 
Step1. CTC Enrichment:​ CTC enrichment technique isolates CTCs based on either 
through their surface antibody or their electric charge or cell size. CellSearch is an example of a 
surface antibody-based technique. Referred to as the "gold standard" by authors, it is the only 
method that's approved by the FDA for diagnosis of breast, colorectal and prostate cancers [36]. 
Step 2.​ ​CTC Detection​: The detection of enriched CTCs is carried out either through 
morphological examination, mRNA analysis or mutational analysis of the DNA.  
Some technologies developed for CTC isolation include ScreenCell, ISET, ApoStream, 
ClearCell FX System and so on.  
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Appendix J 
CNV 
Copy number variation (CNV) refers to an occurrence where sections of a genome are 
repeated, and between individuals, there's a variation of the number of repeats in the genome 
[23]. They are vital in displaying variations within a population, modulating gene expression and 
even disease phenotype. In pancreatic cancer, several genes have been differentially expressed 
due to copy number alterations. Familial pancreatic cancers are as a result of heritable alterations 
in at least a rare major gene.  
In the structural architecture of copy number variations, researchers have identified           
hotspot regions where copy number variations are more enriched in a genome. In these regions,               
they have an increased rate of chromosomal rearrangements that's also responsible for genetic             
diseases. These CNV hotspots are consistent in many populations regardless of your            
ethnographic origin [23].  
For example, analyzing the CNV of mutations in the PRSS1 gene can assist in identifying               
high-risk patients regardless of the ethnographic origin [37]. Developing a screening           
methodology that'll identify the CNV hotspot regions for pancreatic cancers will greatly aid the              
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Appendix K 
The program for this project is written in Python. Values for mass, discount and 
propositions can be defined and modified for a particular frame to test how the changes affect the 
final prediction. Values for propositions and masses for different frames are defined in 
md_input.txt. Discount values for various frames are defined in the pc_discount_rates.py. Code 
in update_md_input.py serves to automate the process of adjusting the mass and proposition 
values for different frames. The program reads definition from md_input_uddate.txt to update the 
values in md_input.txt. In md_input_uddate.txt, an initial mass value, mass increment rule, and a 
list of propositions can be provided for different frames. The automate updating program reads 
the list of propositions for each frame, and updates the mass for each proposition based on mass 
increment rule starting from the initial mass. For example, if for the frame 
DRINKING_HISTORY, the list of propositions given are {(LOW), (MEDIUM), (HIGH)} with 
initial mass 0.2, and mass updating rule is +0.2, then the program will automatically update the 
values for the frame DRINKING_HISTORY in md_input.txt, starting from proposition LOW 
with mass 0.2, then increase mass to 0.4, and keeping increment mass as long as its <= 1.0. After 
that, the program will use the next proposition MEDIUM in the list with the initial mass 0.2, and 
repeat the process to update mass, and this process will be repeated for proposition HIGH as 
well. After each update, the program will also run the evidential reasoning program 
predict_pac_new.py, which reads input parameters from md_input.txt to make predictions and 
record the input mass, propositions for the updated frame along with the outcomes in result.txt.  
If multiple frames are defined in md_input_uddate.txt, the updating program will update 
each frame just like the above example in md_input.txt simultaneously, and record outcomes in 
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result.txt. Mass updating rule can be set as incrementing using “+” sign or decrementing with “-” 
sign in front of the numeric value, if the initial mass is 0.7, and mass update rules is -0.2, then for 
each update, the program will decreatement mass for each proposition till >= 0.0. When defining 
propositions to be updated for each frame, each proposition should be surrounded by a pair of 
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